Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance.
COVID-19
Hematologic neoplasms
Immunosuppression
Virus diseases
Journal
The Medical journal of Australia
ISSN: 1326-5377
Titre abrégé: Med J Aust
Pays: Australia
ID NLM: 0400714
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
pubmed:
14
5
2020
medline:
13
6
2020
entrez:
14
5
2020
Statut:
ppublish
Résumé
A pandemic coronavirus, SARS-CoV-2, causes COVID-19, a potentially life-threatening respiratory disease. Patients with cancer may have compromised immunity due to their malignancy and/or treatment, and may be at elevated risk of severe COVID-19. Community transmission of COVID-19 could overwhelm health care services, compromising delivery of cancer care. This interim consensus guidance provides advice for clinicians managing patients with cancer during the pandemic. During the COVID-19 pandemic: In patients with cancer with fever and/or respiratory symptoms, consider causes in addition to COVID-19, including other infections and therapy-related pneumonitis. For suspected or confirmed COVID-19, discuss temporary cessation of cancer therapy with a relevant specialist. Provide information on COVID-19 for patients and carers. Adopt measures within cancer centres to reduce risk of nosocomial SARS-CoV-2 acquisition; support population-wide social distancing; reduce demand on acute services; ensure adequate staffing; and provide culturally safe care. Measures should be equitable, transparent and proportionate to the COVID-19 threat. Consider the risks and benefits of modifying cancer therapies due to COVID-19. Communicate treatment modifications, and review once health service capacity allows. Consider potential impacts of COVID-19 on the blood supply and availability of stem cell donors. Discuss and document goals of care, and involve palliative care services in contingency planning. This interim consensus guidance provides a framework for clinicians managing patients with cancer during the COVID-19 pandemic. In view of the rapidly changing situation, clinicians must also monitor national, state, local and institutional policies, which will take precedence. Australasian Leukaemia and Lymphoma Group; Australasian Lung Cancer Trials Group; Australian and New Zealand Children's Haematology/Oncology Group; Australia and New Zealand Society of Palliative Medicine; Australasian Society for Infectious Diseases; Bone Marrow Transplantation Society of Australia and New Zealand; Cancer Council Australia; Cancer Nurses Society of Australia; Cancer Society of New Zealand; Clinical Oncology Society of Australia; Haematology Society of Australia and New Zealand; National Centre for Infections in Cancer; New Zealand Cancer Control Agency; New Zealand Society for Oncology; and Palliative Care Australia.
Identifiants
pubmed: 32401360
doi: 10.5694/mja2.50607
pmc: PMC7273031
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
481-489Informations de copyright
© 2020 AMPCo Pty Ltd.
Références
JAMA. 2019 Mar 12;321(10):983-997
pubmed: 30860564
Lancet Oncol. 2020 Apr;21(4):e181
pubmed: 32142621
Zhonghua Xue Ye Xue Za Zhi. 2020 Apr 14;41(4):341-343
pubmed: 32149486
JAMA. 2020 Feb 24;:
pubmed: 32091533
Intern Med J. 2017 Jun;47(6):695-698
pubmed: 28580745
Cochrane Database Syst Rev. 2016 Oct 12;10:CD002042
pubmed: 27731885
N Engl J Med. 2013 May 9;368(19):1771-80
pubmed: 23656642
Bone Marrow Transplant. 2020 Mar 23;:
pubmed: 32203269
J Clin Virol. 2015 Jul;68:1-5
pubmed: 26071326
J Pediatric Infect Dis Soc. 2019 Mar 28;8(1):21-28
pubmed: 29447395
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
J Pain Symptom Manage. 2010 Feb;39(2):291-5
pubmed: 20152591
JAMA. 2020 Mar 13;:
pubmed: 32167538
Bone Marrow Transplant. 2019 Jul;54(7):1058-1066
pubmed: 30385869
Pediatr Infect Dis J. 2007 Mar;26(3):210-6
pubmed: 17484216
Prev Med. 2010 Nov;51(5):421-4
pubmed: 20728466
Int J Antimicrob Agents. 2000 Oct;16(2):93-5
pubmed: 11053786
JAMA. 2020 Mar 3;:
pubmed: 32125362
Trials. 2019 Oct 15;20(1):592
pubmed: 31615553
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Palliat Med. 2004 Jan;18(1):12-8
pubmed: 14982202
Lancet Oncol. 2008 Jun;9(6):585-95
pubmed: 18510990
Clin Infect Dis. 2015 Jul 15;61(2):192-202
pubmed: 25847977
Pediatr Pulmonol. 2020 May;55(5):1169-1174
pubmed: 32134205
Clin Infect Dis. 2013 Jan;56(2):258-66
pubmed: 23024295
Am J Med. 1997 Mar 17;102(3A):2-9; discussion 25-6
pubmed: 10868136
JAMA. 2020 Feb 7;:
pubmed: 32031570
Br J Haematol. 2020 Apr;189(2):279-290
pubmed: 31960409
PLoS One. 2017 Feb 2;12(2):e0170774
pubmed: 28151988
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Pediatr Infect Dis J. 2020 May;39(5):355-368
pubmed: 32310621
BMC Cancer. 2016 Sep 26;16(1):755
pubmed: 27669745
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Transfus Med Rev. 2020 Feb 21;:
pubmed: 32107119
Australas Radiol. 2003 Jun;47(2):143-5
pubmed: 12780442
Lancet Oncol. 2020 Apr;21(4):e180
pubmed: 32142622
Blood. 2014 May 22;123(21):3263-8
pubmed: 24700783
Br J Haematol. 2017 Feb;176(3):365-394
pubmed: 28009056
Biol Blood Marrow Transplant. 2016 Mar;22(3):542-8
pubmed: 26638804
Clin Transl Radiat Oncol. 2020 Mar 24;22:55-68
pubmed: 32274425
Pediatr Radiol. 2020 May;50(6):796-799
pubmed: 32162081
BMJ. 2016 Mar 29;352:i1351
pubmed: 27026510
Transfusion. 2017 Dec;57(12):2903-2913
pubmed: 29067705